The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pneumonitis (interstitial lung disease/ILD)
Causality assessment can be problematic in patients on concomitant infliximab and methotrexate or azathioprine
Publications
Infliximab-Induced Interstitial Pneumonitis: A Case Report.
Cureus. 2023;15(6):e40812
Respiratory symptoms in a patient with inflammatory bowel disease.
Clinical medicine (London, England). 2018;18(2):186-187
Noninfectious interstitial lung disease during infliximab therapy: case report and literature review.
World journal of gastroenterology. 2013;19(32):5377-80
Respiratory failure due to infliximab induced interstitial lung disease.
Heart & lung : the journal of critical care. 2013;42(6):480-2
Infliximab-induced nonspecific interstitial pneumonia.
The American journal of the medical sciences. 2012;344(1):75-8
Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk.
Seminars in arthritis and rheumatism. 2010;40(2):147-63
Infliximab-induced non-specific interstitial pneumonia and lupus-like eruption.
European journal of internal medicine. 2006;17(7):520